Today's edition · Wednesday, November 18, 2026
Every story verifiedNo politics. Ever.No pop-ups
TodayLocalWorldHeroesAnimalsScienceCommunityHealth & TechMapQuizKindnessAnnouncementsKidsTopicsExplainersOn this dayCalendarGood NeighborHometown Heroes

TodayHealth & TechMaryland

Health & TechSilver Spring, Maryland

The FDA approved a pre-surgery bladder cancer combo

The FDA approved durvalumab, sold as Imfinzi, plus enfortumab vedotin before bladder removal, then durvalumab afterward, for muscle-invasive bladder cancer in patients who cannot take cisplatin or who decline it. In the 695-patient VOLGA trial the combo cut the risk of an event by about half. It is not a cure.

Verified · Source: U.S. Food and Drug AdministrationNov 13, 2026 · 1 min read
How to help
A row of glass laboratory beakers on a white surface
Illustrative photo of laboratory beakers. This is not the VOLGA trial, and no patient is pictured. Wikimedia Commons · CC BY-SA 2.5

Read the original

The reporting lives at U.S. Food and Drug Administration. Our summary is checked against it, and we link it on every story.

The Food and Drug Administration on Nov. 13 approved durvalumab, sold as Imfinzi, given with enfortumab vedotin before the bladder is removed, followed by durvalumab afterward. The approval is for muscle-invasive bladder cancer in adults who cannot take cisplatin or who decline it. In the 695-patient VOLGA trial, the combination cut the risk of an event by about half, an event-free survival hazard ratio of 0.51, and improved overall survival, a hazard ratio of 0.58, compared with surgery alone. The agency approved the use six weeks early. Those ratios describe this trial, not every person with bladder cancer. The trial results were reported earlier from UCLA. This step is the approval that makes the regimen an FDA-cleared option. It is not a cure.

More good news

Other stories in the same neighborhood of kindness.

A scientist in a white coat working with sample tubes at a laboratory benchHealth & Tech
Silver Spring, Maryland

The FDA approved the first drug for a rare kidney disease

The FDA approved Gazyva, obinutuzumab, for adults with primary membranous nephropathy at risk of getting worse, to induce remission of protein in the urine. In a 142-person trial, 36 percent reached complete remission at week 104, compared with 6 percent on tacrolimus. It is not a cure.

Verified · U.S. Food and Drug Administration